Intermittent thiazide therapy in recurrent stone formers.
An intermittent thiazide regimen consisting of bendrofluazide, 5 mg. daily, with potassium supplements was given to 17 recent stone formers for period ranging between fifteen months to eight years (mean four years two months). No new stone formation was evident in 8 patients with no radiologic evidence of stones on starting treatment who previously had a stone incidence rate of 0.59 incidents per patient-year. In an additional 9 patients with radiologic evidence of stones on starting treatment the stone recurrence rate was reduced from 0.45 to 0.34 incidents per patient-year. Mild side effects were observed in 2 patients which resolved on discontinuing the treatment regimen.
D000328:Adult; D000368:Aged; D001539:Bendroflumethiazide / Q000008:administration & dosage* / Q000009:adverse effects; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007669:Kidney Calculi / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011188:Potassium / Q000008:administration & dosage; D012008:Recurrence
D001539:Bendroflumethiazide; D011188:Potassium